Roche's Genentech Breaks Ground on North Carolina Manufacturing Site

Dow Jones

08/26

By Katherine Hamilton

Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina.

The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast.

The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said.

The facility is scheduled to be completed and operational by 2029.

The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

August 25, 2025 14:58 ET (18:58 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562922478"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562922478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562922478?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 02:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562922478","market":"hk","top_or_hot":-1,"title":"Roche's Genentech Breaks Ground on North Carolina Manufacturing Site","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina. \n</p>\n<p>\n  The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast. \n</p>\n<p>\n  The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said. \n</p>\n<p>\n  The facility is scheduled to be completed and operational by 2029. \n</p>\n<p>\n  The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 25, 2025 14:58 ET (18:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Genentech Breaks Ground on North Carolina Manufacturing Site</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Genentech Breaks Ground on North Carolina Manufacturing Site\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-26 02:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina. \n</p>\n<p>\n  The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast. \n</p>\n<p>\n  The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said. \n</p>\n<p>\n  The facility is scheduled to be completed and operational by 2029. \n</p>\n<p>\n  The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 25, 2025 14:58 ET (18:58 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2562922478","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562922478","pubTimestamp":1756148280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina.The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast.The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said.The facility is scheduled to be completed and operational by 2029.The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","03165":"华夏欧优股对冲","CARO":"Carolina Financial Corporation","BK4007":"制药"},"translate_title":"罗氏基因泰克在北卡罗来纳州生产基地破土动工","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"CARO":1,"RHHBY":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Roche's U.S. subsidiary Genentech on Monday broke ground on a new $700 million manufacturing facility in North Carolina. \n\n\n  The facility is designed to produce metabolic medicines, including treatments for obesity, and will be 700,000 square feet. Located in Holly Springs, N.C., it is Genentech's first manufacturing site on the east coast. \n\n\n  The facility will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during its development phase, Genentech said. \n\n\n  The facility is scheduled to be completed and operational by 2029. \n\n\n  The project is part of a commitment Roche made in April to spend $50 billion on manufacturing, infrastructure, and research and development in the U.S. over the next five years. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 25, 2025 14:58 ET (18:58 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}